A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection

A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection - A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025608

Enrollment

160

Registered

2017-01-11

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Repsratory Syncytial virus: RSV

Interventions

In intervention group, PO 7mg/kg per day as pranlukast hydrate, in 2 divided doses for 28days in addition to supportive care as usual In control group, supportive care as usual

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children hospitalized with RSV bronchiolitis

Exclusion criteria

Exclusion criteria: Children with comorbidity

Design outcomes

Primary

Measure	Time frame
We evaluate whether internal use of pranlukast from an early stage after hospitalization contributes to the reduction of symptom within onset one month in children hospitalized with acute wheezing caused by RS virus infection.	—

Countries

Japan

Contacts

Public ContactSuguru Takeuchi

Nagoya University Graduate School of Medicine Pediatrics/Developmental pediatrics

suguru-t@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026